Venetoclax (Venclyxto®)
Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL)
Rapid Review
| Commenced | Completed | Outcome |
| 03/01/2017 | 08/02/2017 | Full HTA not recommended until further evidence available |
| 08/05/2018 | 21/06/2018 | Following a resubmission of the rapid review a full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with current available therapies. |
The HSE has approved reimbursement following confidential price negotiations – December 2018.